Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Clinical trials during COVID-19.
Bringing the clinical trial to the patient with innovation and in-home solutions.
ICON provides its full range of clinical, consulting and commercial services across several industry sectors.
A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
Serving governments, multinational public health organisations, and global NGOs.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
Connecting patients with the right trial in the right location.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Aggregated news on COVID-19 clinical trials.
Patient focused research for better outcomes.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
Trial capabilities key to enabling agility and speed in global study involving 44,000 subjects.
3 February, 2021
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
ICON is committed to making a positive impact on our people, environment and our community.
Partners making a difference.
Download our case study to discover ICON’s operational expertise, proven execution processes & technologies that maintain study blinding & prevent operational bias in adaptive design trials -- increasing clients' chances of success
After running for seven years, an adaptive Phase II trial for acute infectious diarrhea fell prey to operational bias during interim analysis. Learn which procedures could have enabled the study to maintain blinding.
Learn how ICON’s operational expertise, proven execution processes, and technologies maintain study blinding and prevent operational bias in adaptive design trials. Download your copy today.